Developing new treatments to target a protein linked to heart disease
Computational Development of Novel Dyslipidemia Therapeutic Candidates to Disrupt ApoC-III Conformation
This study is looking at how a protein called ApoC-III affects heart health, especially for people who have high cardiovascular risk even when their LDL cholesterol is low, and the researchers are trying to find new treatments that can help clear this protein from the blood to improve heart health.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Imetabolic Biopharma Corporation NIH-funded |
| Lab location | 1 site (Tempe, United States) |
| Project ID | NIH-10760187 on NIH RePORTER |
What this research studies
This research focuses on cardiovascular disease, particularly the role of apolipoprotein C-III (ApoC-III) in maintaining high cardiovascular risk despite low levels of LDL cholesterol. The team at iMBP is using computational methods to design novel therapeutic candidates that can disrupt the harmful conformation of ApoC-III, which is known to inhibit important processes in lipid metabolism. By targeting this protein, the research aims to improve treatment options for patients who are at risk for cardiovascular events due to triglyceride-rich lipoprotein particles. The approach involves identifying compounds that can effectively alter the structure of ApoC-III to enhance its clearance from the bloodstream.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with elevated triglyceride levels and a history of cardiovascular disease.
Not a fit: Patients who have normal triglyceride levels and do not have cardiovascular risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for reducing cardiovascular risk in patients with high levels of triglycerides.
How similar studies have performed: Previous research has shown promise in targeting ApoC-III for cardiovascular disease treatment, indicating that this approach could be a meaningful advancement.
Where this research is happening
Tempe, United States
- Imetabolic Biopharma Corporation — Tempe, United States (Active)
Researchers
- Principal investigator: Kiernan, Urban a — Imetabolic Biopharma Corporation
- Study coordinator: Kiernan, Urban a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.